

PROCESS FLOW FOR A POTENTIAL/ACTUAL CRITICAL MEDICINE OR DEVICE* SHORTAGE AND APPROPRIATE ACTION**

Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA) Working Group

The ACCC interim authorisation allows the MA/GBMA Working Group to implement a coordinated strategy in relation to the supply of:

- prescription-only medicines that are critical to patient health, including medicines used to treat patients suffering from the symptoms of COVID-19 (Critical Medicines);
- devices or services that are supplied or administered with Critical Medicines, and therefore essential to the efficacy and proper administration of Critical Medicines (Critical Devices)*
- and to address shortages in the supply of Critical Medicines and Critical Devices that arise as a result of COVID-19.

Working Group - Level 1:

- TGA
- MA Secretariat (Liz deSomer)
- GBMA Secretariat (Marnie Peterson)

Working Group - Level 2

- TGA
- MA Secretariat (Liz deSomer)
- GBMA Secretariat (Marnie Peterson)
- Identified manufacturers/sponsors of critical medicine/device (attendance voluntary)

Working Group - Level 3

- TGA
- MA Secretariat (Liz deSomer)
- GBMA Secretariat (Marnie Peterson)
- Identified manufacturers/sponsors of critical medicine/device (attendance voluntary)
- NPSA/Wholesalers

New member ACCC advice†:

- Association Secretariat to advise lawyer of new member
- Email directly to Clayton Utz
- Association Secretariat to copy alternative Association Secretariat on email

